Kirkland Advises SR One in Spinout from GlaxoSmithKline and Fundraising for $500M SR One Capital Fund I
Kirkland & Ellis represented trans-Atlantic biotech venture capital firm SR One Capital Management in its successful spinout from GlaxoSmithKline (GSK) and the close of its first independent fund. GSK is the largest investor in the oversubscribed $500 million fund, joined by a global pool of institutional asset managers, endowments, foundations, pension funds and family offices. SR One will seek to continue to build elite biotechnology companies developing innovative medicines that address significant unmet needs.
Read SR One’s press release
The cross-office team was led by transactional partner Kamran Bajwa and investment funds partners Andrew Day and Jean Jeong and associates Nicole Chiang and Nicole Pennycooke. The team also included investment funds partners Amala Ejikeme and Barry Le Vine, corporate associates Brandon Elliott, Adam Birnbaum and Brian Guerinot, debt finance associate Camille Doom, tax partners Ian Ferreira and Steve Butler and associates Emma Faulkner and Courtney Loyack, investment funds partners Josh Westerholm and Phil Giglio and associate Radhika Kshatriya, financial services regulatory partners Colin Sharpsmith and Lisa Cawley, banking regulatory of counsel Julie Kunetka, executive compensation partner Scott Price, employee benefits partner Liz Dyer, litigation partner Nick Niles, IP litigation partner Mary Mazzello, and international trade and national security associate Luci Hague.
